Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America

Pontifical Catholic University of Argentina

Status: Completed

Conditions: Osteoporosis

Treatments: Drug: antiresorptive therapy

Study type: Observational

Funder types: Other

Identifiers

NCT02635997

Catholic University

Details and patient eligibility

About

Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.

Enrollment: 425 patients

Sex: Female

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with a diagnosis of osteoporosis of at-Risk
• Have a medical indication to receive Ibandronate+Vitamine D+Calcium

Exclusion criteria

• Osteoporosis due to secondary causes

Trial design

425 participants in 1 patient group

patients on antiresorptive therapy

Description:

Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day

Treatment:

Drug: antiresorptive therapy